Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer

Li,Zhengguang; Wu,Jun; Ji,Mei; Shi,Liangrong; Xu,Bin; Jiang,Jingting; Wu,Changping

doi:10.3892/mco.2014.301

Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer

Authors:
- Zhengguang Li
- Jun Wu
- Mei Ji
- Liangrong Shi
- Bin Xu
- Jingting Jiang
- Changping Wu
View Affiliations

Affiliations: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: June 3, 2014 https://doi.org/10.3892/mco.2014.301
Pages: 756-760

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of gastric cancer has been unsatisfactory thus far; therefore, novel targets and treatment strategies are urgently required. Lemur tyrosine kinase (LMTK)3 is an estrogen receptor‑α (ERα) modulator with a central role in endocrine resistance in breast cancer. Moreover, the expression and polymorphisms of LMTK3 are correlated with the prognosis of breast cancer patients. Since estrogen receptor (ER) is also expressed and plays a role in gastric cancer, we herein investigated the expression of the LMTK3 protein in 83 gastric cancer patients by tissue microarray and analyzed the correlation between LMTK3 expression and the prognosis of gastric cancer. Our results demonstrated that LMTK3 was more frequently expressed in gastric cancer tissues compared to non‑cancerous mucosa (79.5 vs. 45.8%, respectively; P=0.000). The LMTK3 expression was significantly correlated with the depth of invasion (P=0.002) and disease stage (P=0.035). The Kaplan‑Meier analysis revealed that the postoperative survival of the LMTK3‑negative group was superior to that of the LMTK3‑positive group (P=0.043). Moreover, the multivariate analysis identified LMTK3 expression as an independent prognostic factor for patients with gastric cancer (P=0.019). These findings suggested that the expression of LMTK3 may be a negative prognostic factor in patients with gastric cancer. Moreover, targeting LMTK3 is a potential strategy for the treatment of gastric cancer, although the biological functions of LMTK3 in gastric cancer require further investigation.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
3	Huang JY, Xu YY, Sun Z, et al: Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 13:4379–4385. 2012. View Article : Google Scholar
4	Meyer HJ and Wilke H: Treatment strategies in gastric cancer. Dtsch Arztebl Int. 108:698–705. 2011.
5	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
6	De Vita F, Giuliani F, Silvestris N, et al: Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets. 16(Suppl 2): S29–S34. 2012.PubMed/NCBI
7	Naik S, Dothager RS, Marasa J, Lewis CL and Piwnica-Worms D: Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant beta-catenin activation in colon cancer. Clin Cancer Res. 15:7529–7537. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tyner JW, Deininger MW, Loriaux MM, et al: RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 106:8695–8700. 2009. View Article : Google Scholar : PubMed/NCBI
9	Giamas G, Filipovic A, Jacob J, et al: Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 17:715–719. 2011. View Article : Google Scholar : PubMed/NCBI
10	Stebbing J, Filipovic A, Ellis IO, et al: LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat. 132:537–544. 2011. View Article : Google Scholar : PubMed/NCBI
11	Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P and Rabkin CS: Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 21:20–38. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sheh A, Ge Z, Parry NM, et al: 17β-estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice. Cancer Prev Res (Phila). 4:1426–1435. 2011.
13	Ryu WS, Kim JH, Jang YJ, et al: Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol. 106:456–461. 2012. View Article : Google Scholar : PubMed/NCBI
14	Xu CY, Guo JL, Jiang ZN, et al: Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol. 17:2503–2509. 2010. View Article : Google Scholar : PubMed/NCBI
15	Deng H, Huang X, Fan J, et al: A variant of estrogen receptor-α, ER-α36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep. 24:171–176. 2010.
16	Zhou J, Teng R, Xu C, et al: Overexpression of ERα inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing β-catenin. Oncol Rep. 30:1622–1630. 2013.
17	Cho JY: Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer. 13:129–135. 2013. View Article : Google Scholar : PubMed/NCBI
18	Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
19	Jorgensen JT and Hersom M: HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer. 3:137–144. 2012. View Article : Google Scholar : PubMed/NCBI
20	Furukawa H, Iwanaga T, Koyama H and Taniguchi H: Effect of sex hormones on the experimental induction of cancer in rat stomach - a preliminary study. Digestion. 23:151–155. 1982. View Article : Google Scholar : PubMed/NCBI
21	Lindblad M, Ye W, Rubio C and Lagergren J: Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev. 13:2203–2207. 2004.PubMed/NCBI
22	Chandanos E and Lagergren J: Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 44:2397–2403. 2008. View Article : Google Scholar : PubMed/NCBI
23	Gan L, He J, Zhang X, et al: Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer. 12:5662012. View Article : Google Scholar : PubMed/NCBI
24	Matsuyama S, Ohkura Y, Eguchi H, et al: Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol. 128:319–324. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wang M, Pan JY, Song GR, Chen HB, An LJ and Qu SX: Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 33:195–201. 2007. View Article : Google Scholar
26	Chandanos E, Rubio CA, Lindblad M, et al: Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer. 11:168–174. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kitaoka H: Chemo-endocrine therapy of diffuse carcinoma of the stomach and its clinical evaluation. Jpn J Cancer Clinics. 31(Suppl 9): 1189–1194. 1985.(In Japanese).
28	Harrison JD, Morris DL, Ellis IO, Jones JA and Jackson I: The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer. 64:1007–1010. 1989. View Article : Google Scholar : PubMed/NCBI
29	Kojima O and Takahashi T: Endocrine therapy of scirrhous carcinoma of the stomach. Jpn J Cancer Chemother. 13:2526–2531. 1986.(In Japanese).
30	Kitaoka H: Sex hormone dependency in diffuse carcinoma of the stomach and results of chemo-endocrine therapy. Jpn J Cancer Clinics. 30(Suppl 6): 741–748. 1984.(In Japanese).
31	Kim MJ, Cho SI, Lee KO, Han HJ, Song TJ and Park SH: Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines. J Gastric Cancer. 13:172–178. 2013.
32	Shi H, Wu J, Ji M, et al: Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis. Med Oncol. 30:7542013. View Article : Google Scholar : PubMed/NCBI
33	Wakatsuki T, LaBonte MJ, Bohanes PO, et al: Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 12:2261–2272. 2013. View Article : Google Scholar : PubMed/NCBI